Multiple sclerosis is linked to MAPK^ERK overactivity in microglia

Area of Science:

• Neuroimmunology
• Neurodegeneration
• Molecular Biology

Background:

• Multiple sclerosis (MS) pathophysiology is primarily viewed as autoimmune.
• Microglial dysfunction has been implicated in neurodegenerative processes.
• Mitogen-activated protein kinase (MAPK) pathways, particularly MAPK^ERK, are increasingly recognized in neurodegeneration.

Purpose of the Study:

• To reassess published observations in MS patients to propose a new pathophysiological concept.
• To investigate the role of microglial mitogen-activated protein kinase ERK (MAPK^ERK) overactivity in MS.
• To explore potential novel therapeutic targets for refractory MS.

Main Methods:

• Reanalysis of existing biochemical and epigenetic data from MS patients.
• Review of preclinical research on MAPK pathways in neurodegeneration.
• Correlation of known MS risk factors with MAPK^ERK pathway regulation.

Main Results:

• Published data suggest microglial malfunction due to inappropriate MAPK^ERK overactivity in MS.
• MAPK^ERK overactivity in microglia can disturb oligodendrocytes, leading to demyelination.
• MS risk factors (EBV, hypovitaminosis D, smoking) downregulate MAPK^ERK negative feedback, potentially causing pathway overactivity.

Conclusions:

• Microglial MAPK^ERK overactivity presents a novel pathophysiological concept for MS, distinct from autoimmunity.
• This pathway dysfunction may explain persistent neurodegeneration in MS patients undergoing treatment.
• Targeting MAPK^ERK overactivity in microglia could represent a new therapeutic strategy for progressive and refractory MS.